<DOC>
	<DOCNO>NCT00600054</DOCNO>
	<brief_summary>This phase 2 , single-arm , multi-center study , safety review component , design evaluate efficacy safety nimotuzumab approximately 44 patient recurrent diffuse intrinsic pontine glioma ( DIPG ) follow one previous regimen disease . Patients must diagnose radiologically verified recurrent diffuse intrinsic pontine glioma measurable least two dimension . Patients eligible without histologic confirmation . Treatment regimen consist two phases-induction consolidation .</brief_summary>
	<brief_title>Phase 2 Study Nimotuzumab Pediatric Recurrent Diffuse Intrinsic Pontine Glioma</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Signed write informed consent Patients recurrent , diffuse intrinsic pontine glioma Patients 2 follow 3 neurological symptom : cranial nerve deficit , long tract sign , ataxia onset prior initial diagnosis &lt; 6 month . Evidence disease progression Have Lansky Karnofsky Performance Status &gt; 40 Be age &gt; 3 year &lt; 18 year age Have tumor measurable radiologically For female patient childbearing age : presence negative pregnancy test within 7 day prior day 0 . Use effective contraception Adequate hematological , renal , hepatic function A history prior use EGFRtargeting agent ( monoclonal antibody , tyrosine kinase inhibitor ) More one line treatment Patients disseminate disease eligible Had radiation therapy complete within 12 week enrollment Previous chemotherapy complete &lt; 2 week prior enrollment If female , pregnant lactating Has exist serious medical condition Has condition , therapy , medical condition , , opinion attend physician could represent risk patient adversely affect study objective Is currently take plan take investigational drug study Known contraindication antibody</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Diffuse intrinsic pontine glioma</keyword>
	<keyword>Common Terminology Criteria</keyword>
	<keyword>Epidermal Growth factor receptor</keyword>
	<keyword>Human antihuman antibody</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>monoclonal antibody</keyword>
	<keyword>Informed Consent Form</keyword>
</DOC>